Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety and efficacy of difamilast ointment in adult and pediatric atopic dermatitis
jRCT2080224660Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of difamilast in atopic dermatitis (AD) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety of difamilast ointment. Started Apr 2019; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224660.